| Accreditation Statement |
| This activity is jointly sponsored by the Medical Education Collaborative, Inc. (MEC) and Insight Medical Communications Inc. |
 |
| This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of MEC and Insight Medical Communications Inc. MEC is accredited by the ACCME to provide continuing medical education for physicians. |
|
| MEC designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| |
| Sponsorship Statements |
| This symposium is being held in conjunction with the American Diabetes Association's 67 th Scientific Sessions. |
| Supported through an educational grant from Daiichi Sankyo, Inc. |
| |
| Statement of Need |
| Through recent research, many new receptors and metabolic pathways that impact on the progression of type 2 diabetes have been discovered, and the number of therapeutic choices for treating patients with type 2 diabetes continues to increase. Despite this, a majority of patients with type 2 diabetes are not meeting targeted lipid or glycemic goals. The gap between targeted and accomplished goals has serious implications for the reduction of diabetic complications, particularly cardiovascular disease. A currently available treatment option offers the potential to overcome these challenges. A novel strategy to achieve both lipid and glycemic goals is to incorporate bile acid sequestrants into existing diabetes treatment regimens. These agents exploit a unique metabolic pathway through the liver and intestine, which has the potential to bring both LDL-C and glucose levels closer to goal. As a result, the cardiovascular risk of patients may be reduced. |
| |
| Learning Objectives |
- Describe the major biological processes involved in the enterohepatic circulation of bile acids
- Explain the role of nuclear receptors in the control of bile acid synthesis
- List potential mechanisms by which bile acid sequestrants may affect both lipid and glucose metabolism
- Discuss the clinical evidence for the ability of bile acid sequestrants to affect both lipid and glucose levels in patients with type 2 diabetes mellitus
|
| Target Audience |
| Physicians, pharmacists, nurse practitioners, physician assistants, diabetes educators, and allied healthcare professionals |
| |
| Faculty List |
| Vivian A. Fonseca, MD, FRCP, Chair |
Professor of Medicine
Director, Diabetes Program
Tulane University Health Sciences Center
New Orleans, Louisiana |
|
| David E. Cohen, MD, PhD |
Associate Professor of Medicine
Harvard Medical School
Associate Professor of Health Sciences Technology
Harvard-Massachusetts Institute of Technology
Boston , Massachusetts |
|
| Steven A. Kliewer, PhD |
Professor, Molecular Biology
University of Texas Southwestern Medical School
Graduate School of Biomedical Sciences
Dallas , Texas |
| |
| Faculty Disclosures |
| Disclosure Policy |
It is the policy of Medical Education Collaborative (MEC) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. All faculty/authors participating in our programs are expected to disclose any relationships they may have with commercial companies whose products or services may be mentioned so that participants may evaluate the objectivity of the presentations. |
|
| Disclaimer |
The content and views presented in this educational program are those of the faculty and do not necessarily reflect those of MEC, Insight Medical Communications Inc., or Daiichi Sankyo, Inc. All faculty will disclose if any unlabeled use of products is mentioned in his/her presentation. Before prescribing any medicine, primary references and full prescribing information should be consulted. |
|
| MEC Disclaimer |
| The employees of MEC have no financial relationships to disclose. |
|
| Vivian A. Fonseca, MD, FRCP |
| Grants/research support: |
GlaxoSmithKline, Novartis, Takeda, Astra-Zeneca, Pfizer, Sanofi-Aventis, Eli Lilly, Daiichi-Sankyo, Novartis, NIH, ADA |
| Consulting agreements: |
GlaxoSmithKline, Novartis, Takeda, Pfizer, Sanofi-Aventis, Eli Lilly |
|
| David E. Cohen, MD, PhD |
| Consulting agreements: |
Aegerion, Daiichi Sankyo, Merck, Schering Plough, Takeda |
| Speaker Bureau: |
Merck, Sanofi Aventis, Schering Plough |
|
| Steven A. Kliewer, PhD |
| Consulting agreements: |
Daiichi-Sankyo, Intekrin Pharmaceuticals, GlaxoSmithKline |
| Speaker Bureau: |
Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline |
|
| |
| Credit Designation Statement |
| MEC designates this educational activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM |
| |
| How to Obtain Credit |
| Viewers are expected to view and listen to all presentations before attempting to take the test and activity evaluation. Successful completion will lead to the issuance of a certificate for 1.00 AMA PRA Category 1 CreditsTM or a certificate of participation. To receive credit, the course must be completed before August 1, 2008. |
|
| Participation in this activity should be completed in approximately 1 hour and 15 minutes. |
|
| Please follow these steps in order to receive CME credit for viewing the webcast:
- Read all of the CME accreditation information above.
- View and listen to the complete webcast program.
- Click on the link to apply for CME credit.
- Complete the online registration (registration is free).
- Complete the online test and evaluation. Participants must receive a test score of at least 70% and answer all evaluation questions to receive a certificate.
After successfully completing the online test and evaluation, you may view and print your online certificate. |
| |
| Release Date and Expiration Date |
| 8/2007 – 8/2008 |
| |
| Statement of Evidence Based Content |
| Discussions with opinion leaders in the fields of endocrinology and cardiology have demonstrated the need to educate physicians about the ongoing problem of reaching target glucose and lipid goals. Importantly, the mechanism by which currently available therapies may help to reach goals is unclear. Speakers for this program will present the science behind nuclear receptors, bile acid metabolism and their implications for controlling glucose and lipid levels in diabetic patients. Potential mechanisms of action will be presented, with the goal of stimulating a discussion between the audience and presenters. |
| |
| Commercial Support Statement |
| Supported through an educational grant from Daiichi Sankyo, Inc. |
| |
| Details to Contact CME Provider |
Angela Noreen
Account Manager
Medical Education Collaborative
651 Corporate Circle, Ste. 104 / Golden CO 80401
T 303.420.3252 x24 / 866.420.3252
F 303.420.3259 / anoreen@meccme.org |
| |
